Drug Pricing
Commentary
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Commentary
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Blog
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
Drug Prices
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
Commentary
Kennedy’s Vaccine Policies Put Americans at Risk in More Ways Than One
The effects of Kennedy’s vaccines policies are going to hurt Americans – and not just because more people are falling ill. Health experts, former CDC directors, and medical associations are gravely concerned that HHS Secretary RFK Jr.’s actions are risking Americans’ health and wellbeing. Nine former directors of the CDC ...
Commentary
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
Commentary
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Commentary
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Commentary
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
Kennedy’s Vaccine Policies Put Americans at Risk in More Ways Than One
The effects of Kennedy’s vaccines policies are going to hurt Americans – and not just because more people are falling ill. Health experts, former CDC directors, and medical associations are gravely concerned that HHS Secretary RFK Jr.’s actions are risking Americans’ health and wellbeing. Nine former directors of the CDC ...
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
